首頁 > 市場調查報告書 > 製藥

神經疾病

市場調查報告書

商品編碼

1494398

2030 年亞太地區癲癇藥物市場預測 - 區域分析 - 按治療和配銷通路

Asia Pacific Epilepsy Drugs Market Forecast to 2030 - Regional Analysis - by Treatment and Distribution Channel

出版日期: 2024年03月14日 | 出版商:

The Insight Partners | 英文 71 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

2022年亞太地區癲癇藥物市值為21.9872億美元，預計2030年將達到31.4344億美元；預計2022年至2030年複合年成長率為4.6%。

老年人數量的增加推動了亞太地區癲癇藥物市場的發展

預計未來幾年癲癇藥物市場的許多專利將到期。它可能會增加學名藥的滲透率，以減少醫療費用。這將為其他市場參與者創造更多機會。以下提到的是一些在未來幾年內專利即將到期的藥物。

公司專利專利有效期限成分處理

住友製藥公司 US9206135 2026年4月21日醋酸艾斯利卡西平部分發作性癲癇發作

葛蘭素史克 US7919115 2029 年 1 月 4 日拉莫三嗪癲癇

Ucb Inc USRE38551 2022 年 3 月 17 日拉科醯胺癲癇與局部發作癲癇

SK Biopharmaceuticals US7598279 2027 年 10 月 30 日 CENOBAMATE 局部性癲癇

SUPERNUS PHARMS US8877248 2027 年 11 月托吡酯癲癇緩釋製劑

SUPERNUS PHARMS US9555004 2027 年 11 月托吡酯癲癇緩釋製劑

SUPERNUS PHARMS US10314790 2027 年 11 月托吡酯癲癇緩釋製劑

SUPERNUS PHARMS US8663683 2027 年 11 月托吡酯癲癇緩釋製劑

SUPERNUS PHARMS US9622983 2027 年 11 月托吡酯癲癇緩釋製劑

SUPERNUS PHARMS US8298580 2027 年 11 月托吡酯癲癇緩釋製劑

SUPERNUS PHARMS US8992989 2027 年 11 月托吡酯癲癇緩釋製劑

SUPERNUS PHARMS US8889191 2027 年 11 月托吡酯癲癇緩釋製劑

SUPERNUS PHARMS US9549940 2027 年 11 月托吡酯癲癇緩釋製劑

SUPERNUS PHARMS US8298576 2028 年 4 月托吡酯癲癇緩釋製劑

亞太地區癲癇藥物市場概況

根據中國、日本、印度、澳洲、韓國和亞太其他地區分析了亞太地區癲癇藥物市場。根據世界衛生組織（WHO）報告，癲癇在發展中國家比已開發國家更為常見，盛行率分別為6.1%和5.0%。中國是世界上人口最多的國家，也是神經系統疾病患者最多的國家。根據疾病預防控制中心統計，在我國，活動性癲癇的盛行率為0.48%～8.5%；中國大陸約有900萬癲癇患者，其中三分之二是兒童。約 30% 的癲癇患者無法使用目前市面上販售的 AED 控制癲癇發作；因此，這種疾病的醫療需求顯著未被滿足。

此外，該國的藥品批准正在推動市場成長。例如，2021年8月，衛材株式會社獲得了抗癲癇藥物（AED）Fycompa的兩項額外批准，作為「部分性癲癇發作的單一療法」和「部分性癲癇發作的兒科適應症的輔助治療/單一療法」。國家藥品監督管理局發布的《中國四歲及以上癲癇患者癲癇發作的情況》。

亞太地區癲癇藥物市場收入及 2030 年預測（百萬美元）

亞太地區癲癇藥物市場細分

亞太地區癲癇藥物市場按治療、配銷通路和國家細分。

根據治療，亞太地區癲癇藥物市場分為第一代抗癲癇藥物、第二代抗癲癇藥物和第三代抗癲癇藥物。 2022年，第三代抗癲癇藥物佔最大佔有率。

從配銷通路來看，亞太地區癲癇藥物市場分為醫院藥局、零售藥局等。 2022年，醫院藥局部門佔最大佔有率。

依國家/地區分類，亞太地區癲癇藥物市場分為中國、日本、印度、澳洲、韓國和亞太地區其他地區。 2022年，中國在亞太癲癇藥物市場佔據主導地位。

雅培實驗室、阿爾肯實驗室有限公司、葛蘭素史克公司、諾華公司、輝瑞公司、賽諾菲公司和梯瓦製藥工業有限公司是亞太地區癲癇藥物市場上的一些領先公司。

Many patents expiries are anticipated in the epilepsy drugs market in the upcoming years. It is likely to increase the penetration of generic products to cut down healthcare expenses. This will generate additional opportunities for other market players. Below mentioned are some drugs that are nearing patent expiration in the next couple of years.

Company Patent Patent Expiration Date Ingredient Treatment

Sumitomo Pharma Co US9206135 April 21, 2026 ESLICARBAZEPINE ACETATE Partial-onset Seizures Epilepsy

GlaxoSmithKline US7919115 January 4, 2029 LAMOTRIGINE Epilepsy

Ucb Inc USRE38551 March 17, 2022 Lacosamide Epilepsy and Partial-onset Seizures

SK Biopharmaceuticals US7598279 October 30, 2027 CENOBAMATE Partial Epilepsies

SUPERNUS PHARMS US8877248 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9555004 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US10314790 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8663683 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9622983 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8298580 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8992989 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8889191 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9549940 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8298576 April, 2028 Sustained-release formulations of Topiramate Epilepsy

Asia Pacific Epilepsy Drugs Market Overview

The Asia Pacific epilepsy drugs market is analysed based on China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. According to the World Health Organization (WHO) report, epilepsy is more common in developing countries than in developed countries, accounting for a prevalence of 6.1% and 5.0%, respectively. China is the most populated country in the world and the one with the most patients with neurological disorders. According to the Centers of Disease Control and Prevention, in China, the prevalence rate of active epilepsy is 0.48% to 8.5%; there are approximately 9 million people with epilepsy in Mainland China, two-thirds of whom are children. ~30% of patients with epilepsy are not capable of controlling their seizures with the AEDs that are currently available in the market; thus, this disease has significant unmet medical needs.

Moreover, the drug approvals in the country are propelling the market growth. For instance, in August 2021, Eisai Co., Ltd. obtained two additional approvals of the antiepileptic drug (AED) Fycompa, as "a monotherapy for partial-onset seizures" and "an adjunctive treatment / a monotherapy for a pediatric indication for partial onset seizures in patients with epilepsy four years of age and older" in China from the National Medical Products Administration.

Asia Pacific Epilepsy Drugs Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Epilepsy Drugs Market Segmentation

The Asia Pacific epilepsy drugs market is segmented into treatment, distribution channel, and country.

Based on treatment, the Asia Pacific epilepsy drugs market is classified into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third-generation anti-epileptics segment held the largest share in 2022.

In terms of distribution channel, the Asia Pacific epilepsy drugs market is categorized into hospital pharmacy, retail pharmacy stores, and others. The hospital pharmacy segment held the largest share in 2022.

Based on country, the Asia Pacific epilepsy drugs market is segmented China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific epilepsy drugs market in 2022.

Abbott Laboratories, Alkem Laboratories Ltd, GSK Plc, Novartis AG, Pfizer Inc, Sanofi SA, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the Asia Pacific epilepsy drugs market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Epilepsy Drugs Market Landscape

4.1 Overview

5. Asia Pacific Epilepsy Drugs Market - Key Industry Dynamics

5.1 Market Drivers
- 5.1.1 Growing Prevalence of Epilepsy
- 5.1.2 Increasing Number of Elderly People
5.2 Market Restraints
- 5.2.1 Recall of Therapeutic Products
5.3 Market Opportunities
- 5.3.1 Several Epilepsy Drugs Nearing Patent Expiration
5.4 Future Trends
- 5.4.1 Increasing Product Approvals
5.5 Impact Analysis

6. Epilepsy Drugs Market - Asia Pacific Market Analysis

6.1 Overview
6.2 Asia Pacific Epilepsy Drugs Market Revenue (US$ Mn), 2022 - 2030

7. Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Treatment

7.1 Overview
7.2 Asia Pacific Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
7.3 First Generation Antiepileptics
- 7.3.1 Overview
- 7.3.2 First Generation Antiepileptics: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Second Generation Anti-epileptics
- 7.4.1 Overview
- 7.4.2 Second Generation Anti-epileptics: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Third Generation Anti-epileptics
- 7.5.1 Overview
- 7.5.2 Third Generation Anti-epileptics: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Distribution Channel

8.1 Overview
8.2 Asia Pacific Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacy
- 8.3.1 Overview
- 8.3.2 Hospital Pharmacy: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacy Stores
- 8.4.1 Overview
- 8.4.2 Retail Pharmacy Stores: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
- 8.5.1 Overview
- 8.5.2 Others: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 - Country Analysis

9.1 Asia Pacific Epilepsy Drugs Market, by Key Country- Revenue (2022) (US$ Million)
- 9.1.1 Asia Pacific Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
  - 9.1.1.1 China: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.1.1 Overview
    - 9.1.1.1.2 China: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.1.3 China: Asia Pacific Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.1.1.1.4 China: Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.1.2 Japan: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.2.1 Overview
    - 9.1.1.2.2 Japan: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.2.3 Japan: Asia Pacific Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.1.1.2.4 Japan: Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.1.3 India: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.3.1 Overview
    - 9.1.1.3.2 India: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.3.3 India: Asia Pacific Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.1.1.3.4 India: Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.1.4 Australia: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.4.1 Overview
    - 9.1.1.4.2 Australia: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.4.3 Australia: Asia Pacific Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.1.1.4.4 Australia: Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.1.5 South Korea: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.5.1 Overview
    - 9.1.1.5.2 South Korea: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.5.3 South Korea: Asia Pacific Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.1.1.5.4 South Korea: Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.1.6 Rest of Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.6.1 Overview
    - 9.1.1.6.2 Rest of Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.6.3 Rest of Asia Pacific Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.1.1.6.4 Rest of Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)

10. Epilepsy Drugs Market-Industry Landscape

10.1 Overview
10.2 Growth Strategies in the Epilepsy Drugs Market
10.3 Inorganic Growth Strategies
- 10.3.1 Overview
10.4 Organic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 Novartis AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Pfizer Inc
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 GSK Plc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Abbott Laboratories
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Sanofi SA
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Teva Pharmaceutical Industries Ltd
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Alkem Laboratories Ltd
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms

簡介目錄圖表

List Of Tables

Table 1. Asia Pacific Epilepsy Drugs Market Segmentation
Table 2. China: Asia Pacific Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 3. China: Asia Pacific Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 4. Japan: Asia Pacific Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 5. Japan: Asia Pacific Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 6. India: Asia Pacific Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 7. India: Asia Pacific Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 8. Australia: Asia Pacific Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 9. Australia: Asia Pacific Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 10. South Korea: Asia Pacific Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 11. South Korea: Asia Pacific Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 12. Rest of Asia Pacific Epilepsy Drugs Market, by Treatment - Revenue and Forecast to 2030 (US$ Million)
Table 13. Rest of Asia Pacific Epilepsy Drugs Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 14. Recent Inorganic Growth Strategies in the Epilepsy Drugs Market
Table 15. Recent Organic Growth Strategies in the Asia Pacific Epilepsy Drugs Market
Table 16. Glossary of Terms, Asia Pacific Epilepsy Drugs Market

List Of Figures

Figure 1. Asia Pacific Epilepsy Drugs Market Segmentation, By Country
Figure 2. Asia Pacific Epilepsy Drugs Market: Key Industry Dynamics
Figure 3. Asia Pacific Epilepsy Drugs Market: Impact Analysis of Drivers and Restraints
Figure 4. Asia Pacific Epilepsy Drugs Market Revenue (US$ Mn), 2022 - 2030
Figure 5. Asia Pacific Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
Figure 6. First Generation Anti-epileptics: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Second Generation Anti-epileptics: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Third Generation Anti-epileptics: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Asia Pacific Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
Figure 10. Hospital Pharmacy: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Retail Pharmacy Stores: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Others: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Asia Pacific Epilepsy Drugs Market, by Key Country - Revenue (2022) (US$ Million)
Figure 14. Asia Pacific Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
Figure 15. China: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Japan: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. India: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Australia: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. South Korea: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Rest of Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Growth Strategies in the Epilepsy Drugs Market